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OBJECTIVES: To estimate the average (CER) and incremental (ICER) cost-effective-
ness ratios of surfactant rescue treatment of premature infants with Respiratory
Distress Syndrome (RDS) who are covered by the New Generation Medical Insur-
ance . METHODS: A cost-effectiveness evaluation was conducted from the per-
spective of the Mexican Ministry of Health (SSA). The comparisons were between
bovine surfactant therapy and the alternative of not using it. A decision treemodel
with a two-year time horizon was used, where the measurements of effectiveness
were life years gained (LYG) and quality adjusted life years (QALY). The effective-
ness figures are taken from a systematic review, the resource usage patterns were
obtained from data registered in the SSA hospital files on care, and costs from
official sources in SSA 2009. A 5% discount rate was considered for costs and health
outcomes. Deterministic and probabilistic analyses were conducted. RESULTS:
ICER ratios for surfactant therapy per LYG and per QALY were $61,392 and $62,110,
respectively. CONCLUSIONS: Surfactant therapy was confirmed as a cost-effective
strategy, in accordance toWHO criteria of 3 Per-capita GDP per QALY in premature
infants with RDS in Mexico.
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OBJECTIVES:To estimate the cost effectiveness of dienogest versusGnRHanalogue
(GnRH-a) for the treatment of endometriosis-associated chronic pelvic pain in Slo-
vakia from a payer perspective. METHODS: A cost-utility Markov model based on
results of randomized controlled trial (AU19) was adapted to a Slovakian setting.
The AU19 trial, which compared dienogest and GnRH-a (leuprolide) in the treat-
ment of endometriosis-associated chronic pelvic pain over a 6 month period,
showed no statistically significant differences in response rates. The dienogest
annual relapse rate was derived from 52-weeks extension study, while relapse
rates for the GnRH-awere derived from the literature. Local cost data was based on
published price lists, clinical guidelines, product labels and expert opinion. QoL
related utilities were derived from individual patient SF-36 scores from AU19 da-
taset. Effectiveness was measured in quality-adjusted life years (QALY). Time ho-
rizon was set at 2 years and a payers’ perspective was adopted. Discount rate was
5% per year for both costs and effects according to valid Ministry of Health (MoH)
guidelines for health economic evaluation. Both one-way and probabilistic sensi-
tivity analyses were performed. RESULTS: Dienogest showed that it was cost-
effective compared to a GnRH-a, with an overall cost reduction of 506 € and a
QALY gain of 0.002 per patient. Cost reduction was due to both the differences in
the average drug cost during the two year period (GnRH-a: 1 248 € and dienogest:
969 €) and the average laparoscopy cost (GnRH-a: 274 € and dienogest: 103 €). In
probabilistic sensitivity analysis 69 % of simulations were below 18 000 €/QALY,
which is the officially published threshold for willingness to pay in Slovakia.
CONCLUSIONS: Dienogest is a cost-effective alternative to GnRH analogue for the
treatment of endometriosis-associated chronic pelvic pain in a Slovakian setting.
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OBJECTIVES: Failure to pick up a newly prescribed medication from the pharmacy
is referred to as primary nonadherence. The objective of this retrospective cohort
study is to evaluate primary nonadherence in an integrated closed-network health
care setting. METHODS: All new electronic prescriptions written over a 3-month
period for 11 pre-specified drug classes were identified using electronic health care
data. A prescription was considered new if no medications in the same drug class
were dispensed during the prior year. Patientswere excluded from the study if they
did not have continuousmembership and drug benefits during the 12months prior
and 3 months after the prescription order date, became pregnant during the study
period or were missing age or gender information. Primary nonadherence was
defined as the failure to fill prescriptionswithin 90 days from the day itwaswritten.
Descriptive statistics were used to compare characteristics of adherent prescrip-
tions to nonadherent prescriptions using t-tests and chi-square tests for continu-
ous and categorical variables, respectively. RESULTS: A total of 616,401 new pre-
scriptions were written for 430,098 patients. The overall primary nonadherence
ratewas 8%and themajority of prescriptionswere filled on the sameday as the day
itwaswritten. Nonadherence rateswere slightly higher inmales and older patients
(p0.01).Warfarin products (2%) and anti-infectives (2%) had the lowest nonadher-
ence rates, while analgesics (21%) had the highest nonadherence rate (p0.01). The
primary nonadherence ratewas highest amongprescribers in emergencymedicine
(11%) (p0.01). CONCLUSIONS: This is one of the largest studies examining primary
nonadherence. Primary nonadherence rates found in this study are similar to those of
previous studies using data from a comparable healthcare setting. These results may
be helpful in identifying prescription characteristics associated with higher rates of
primary nonadherence for intervention purposes in the clinical setting.
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OBJECTIVES:Numerous factors pertaining to poormedication adherence in chron-
ically ill patients are well documented, but the paucity of studies concerning ex-
periences during the early treatment course represents a significant knowledge
gap. Interventions targeting this crucial initial phase can significantly influence
long-term adherence and outcomes. An international panel conducted a compre-
hensive, systematic review of the published literature documenting risk factors
related to initial adherence.METHODS: A systematic literature search of Pubmed,
PsychInfo, and Web of Science covered published articles from 1966-2010. Two
independent reviewers abstracted eligible studies through a validated quality in-
strument, documentingmethodological details and factors associated with adher-
ence problems. Articles targeting a variety of behavioral factors were deemed rel-
evant if presenting primary data and quantitative findings following initial
prescriptions. RESULTS: Our search identified 283 potentially relevant publica-
tions; upon full review, 38met eligibility criteria. Themean Nichols quality assess-
ment score was 46.1 (range 11-74), with excellent concordance between indepen-
dent reviewers (r0.923, p0.001). Prevalent terminology defining early
pharmacotherapy was first-fill or initial adherence, yet articles rarely referred to
the very first prescription. Instead, authors examined periods covering 2 weeks to
several years from the index fill, typically the first one to six months. Factors
commonly associated with initial adherence were therapeutic alliance and pro-
vider communication (n9), psychiatric symptoms or disease severity (n6), med-
ication cost/copayments (n5), along with patient demographics and polyphar-
macy. Few studies reported specific health system factors, such as pharmacy
location/information, prescribing provider licensure, or other non-patient
dynamics. CONCLUSIONS: Despite the implications for chronic medication adher-
ence and clinical outcomes, few articles directly examined issues associated with
initial adherence. Notwithstanding this lack of information, many observed risk
factors are amenable to potential interventions, establishing a solid foundation for
appropriate ongoing behaviors. Future research should continue investigating
questions pertaining to initial prescriptions, emerging treatment barriers, and or-
ganizational efforts to promote better long-term adherence.
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OBJECTIVES:Many people underuse themedication prescribed to them for chronic
conditions which undermines their care. Often this underuse is related to the cost
of prescriptions andmay be exacerbated in patients with a traditionally low socio-
economic status. In addition, it has been found that underuse is lower among
patients who express higher satisfaction with the medical care received. We ex-
amined self reported cost-related medication underuse in a sample of black and
white Medicare beneficiaries, and investigated whether racial differences in cost-
related underuse could be explained by differences in satisfaction with care after
controlling for other factors that affect underuse.METHODS: Cross sectional tele-
phone survey of 1031 Medicare beneficiaries 65 years old and older living in Jeffer-
son County, Alabama. Bivariate and multivariable analyses were used to identify
factors associated with delaying or not filling prescriptions because of cost (cost-
related underuse). RESULTS: Of the respondents who had cost-related underuse,
15% were white and 23% were black. Racial disparities were not explained by sat-
isfaction, although low satisfaction was positively associated with cost-related
underuse (adjusted OR1.41, p0.07). In particular, low satisfaction with “expla-
nation on what to do after the doctor visit” was significantly associated with cost-
related underuse. Among 847 who reported adequate income, blacks were 2 times
more likely to have underuse than whites (20% vs 12%, adjusted OR1.9, p.05).
Racial differences in cost-related underuse in the 184 beneficiarieswith inadequate
income were not significant. CONCLUSIONS: Satisfaction with care does not ex-
plain the racial differences, although it has a positive impact on underuse. These
findings suggest that even among those with an income adequate to pay for basic
needs, cost-related underuse is reported by 1 in 6 Medicare beneficiaries. More
research is needed to explain racial disparities in underuse of prescription drugs,
even among beneficiaries who report incomes adequate to meet their needs.
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OBJECTIVES: To evaluate the impact of patient characteristics, behaviors and atti-
tudes on teriparatide adherence in a Medicare Part D plan with a coverage gap.
METHODS: Medicare Part D plan members 18 years and older with at least one
claim for teriparatide in 2009 and continuous enrollment January 1, 2009 – Decem-
ber 31, 2009 were identified in an administrative claims database. A questionnaire
was mailed to members that met study criteria. Descriptive analyses were con-
ducted to evaluate the characteristics of the study population. Logistic regression
analyses were conducted to identify factors that predicted discontinuation with
teriparatide. RESULTS:Out of the 3656mailed questionnaires, 522 (14%) were com-
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